The price-to-earnings ratio for Rigel Pharmaceuticals (NASDAQ: RIGL) is 92.94x, which is above its average ratio. Moreover, the 36-month beta value for RIGL is 1.31. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for RIGL is 17.27M and currently, short sellers hold a 4.68% of that float. On January 20, 2025, RIGL’s average trading volume was 259.69K shares.
RIGL) stock’s latest price update
Rigel Pharmaceuticals (NASDAQ: RIGL)’s stock price has gone rise by 16.02 in comparison to its previous close of 17.35, however, the company has experienced a 23.88% increase in its stock price over the last five trading days. zacks.com reported 2025-01-17 that The average of price targets set by Wall Street analysts indicates a potential upside of 75.8% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
RIGL’s Market Performance
Rigel Pharmaceuticals (RIGL) has experienced a 23.88% rise in stock performance for the past week, with a 5.17% rise in the past month, and a 28.79% rise in the past quarter. The volatility ratio for the week is 9.33%, and the volatility levels for the past 30 days are at 8.04% for RIGL. The simple moving average for the past 20 days is 17.65% for RIGL’s stock, with a 43.64% simple moving average for the past 200 days.
Analysts’ Opinion of RIGL
Many brokerage firms have already submitted their reports for RIGL stocks, with Piper Sandler repeating the rating for RIGL by listing it as a “Neutral.” The predicted price for RIGL in the upcoming period, according to Piper Sandler is $2 based on the research report published on April 03, 2023 of the previous year 2023.
Piper Sandler gave a rating of “Neutral” to RIGL, setting the target price at $1 in the report published on June 08th of the previous year.
RIGL Trading at -3.37% from the 50-Day Moving Average
After a stumble in the market that brought RIGL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.49% of loss for the given period.
Volatility was left at 8.04%, however, over the last 30 days, the volatility rate increased by 9.33%, as shares surge +9.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +43.07% upper at present.
During the last 5 trading sessions, RIGL rose by +23.88%, which changed the moving average for the period of 200-days by +51.35% in comparison to the 20-day moving average, which settled at $17.11. In addition, Rigel Pharmaceuticals saw 19.68% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RIGL starting from Santos David A, who sale 8,918 shares at the price of $1.14 back on Feb 05 ’24. After this action, Santos David A now owns 349,093 shares of Rigel Pharmaceuticals, valued at $10,167 using the latest closing price.
Santos David A, the EVP, Chief Commercial Officer of Rigel Pharmaceuticals, sale 5,601 shares at $1.13 during a trade that took place back on Feb 02 ’24, which means that Santos David A is holding 358,011 shares at $6,329 based on the most recent closing price.
Stock Fundamentals for RIGL
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.89 for the gross margin
The net margin for Rigel Pharmaceuticals stands at 0.02. The total capital return value is set at 0.11.
Based on Rigel Pharmaceuticals (RIGL), the company’s capital structure generated 1.32 points at debt to capital in total, while cash flow to debt ratio is standing at 0.18. The debt to equity ratio resting at -4.12. The interest coverage ratio of the stock is 1.21.
Currently, EBITDA for the company is -16.98 million with net debt to EBITDA at 0.65. When we switch over and look at the enterprise to sales, we see a ratio of 2.31. The receivables turnover for the company is 5.15for trailing twelve months and the total asset turnover is 1.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.96.
Conclusion
To wrap up, the performance of Rigel Pharmaceuticals (RIGL) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
